FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2316484493> ?p ?o ?g. }

• W2316484493 endingPage "26" @default.
• W2316484493 startingPage "20" @default.
• W2316484493 abstract "ABSTRACT: With the rapid advances in the treatment of acute attacks of migraine in the last few years and a number of new treatments, has come the practical clinical problem of comparing emerging acute attack therapies alone and with regard to current treatments. Acute migraine therapies can usefully be regarded as non-specific and specific, from the perspective of migraine, since some medicines, such as aspirin or paracetamol, are used to treat pain more broadly. In this review I will compare both non-specific and specific compounds. To some extent the introduction into trial then clinical use of sumatriptan, the first of the 5HT 1B/1D agonists or triptans, brought new standards in both clinical trial design, and execution and clinical outcome. Thus sumatriptan has become the de facto gold standard and will be thus employed here. To be practical the discussion of the new triptans will be limited to those available widely, naratriptan, rizatriptan and zolmitriptan. There are two broad issues when comparing treatments: what end-point should be considered and then, how can different compounds be compared with respect to that end-point. In terms of end-points those used here relate to pain relief because they have been collected robustly in the clinical studies and, fortunately, rapid pain relief is what patients questioned in population-based studies rate highest in an acute attack medicine. Headache pain has been rated on a scale of nil, mild, moderate and severe and success rated as either a response, nil or mild pain, or headache free, nil pain, at two or four hours. The ideal comparison of the triptans would be a randomized controlled clinical trial directly comparing the medicines in each case. Given that these are not available for all the compounds and the well characterised placebo response in acute migraine studies, summary measures have been developed to express the differences between compounds to try and adjust for the varying placebo effect. The two most widely used are the therapeutic gain, response on active medication minus response on placebo, and the number-needed-to-treat (NNT). The NNT is the reciprocal of the therapeutic gain as a proportion. The strengths and weaknesses of this approach will be discussed, including the importance of the calculation of confidence intervals. It can be concluded that our current instruments are rather blunt and patient preference needs much greater study." @default.
• W2316484493 created "2016-06-24" @default.
• W2316484493 creator A5004525209 @default.
• W2316484493 date "1999-11-01" @default.
• W2316484493 modified "2023-10-15" @default.
• W2316484493 title "The Scientific Basis of Medication Choice in Symptomatic Migraine Treatment" @default.
• W2316484493 cites W1963643315 @default.
• W2316484493 cites W1984136690 @default.
• W2316484493 cites W1992281684 @default.
• W2316484493 cites W2010448526 @default.
• W2316484493 cites W2036354453 @default.
• W2316484493 cites W2036464901 @default.
• W2316484493 cites W2036993928 @default.
• W2316484493 cites W2051450601 @default.
• W2316484493 cites W2068487066 @default.
• W2316484493 cites W2082724548 @default.
• W2316484493 cites W2088590171 @default.
• W2316484493 cites W2091825976 @default.
• W2316484493 cites W2122081700 @default.
• W2316484493 cites W2140200736 @default.
• W2316484493 cites W2149318059 @default.
• W2316484493 cites W2169098250 @default.
• W2316484493 cites W2318612891 @default.
• W2316484493 cites W2521121750 @default.
• W2316484493 cites W3190975204 @default.
• W2316484493 doi "https://doi.org/10.1017/s0317167100000159" @default.
• W2316484493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10563229" @default.
• W2316484493 hasPublicationYear "1999" @default.
• W2316484493 type Work @default.
• W2316484493 sameAs 2316484493 @default.
• W2316484493 citedByCount "39" @default.
• W2316484493 countsByYear W23164844932012 @default.
• W2316484493 crossrefType "journal-article" @default.
• W2316484493 hasAuthorship W2316484493A5004525209 @default.
• W2316484493 hasBestOaLocation W23164844931 @default.
• W2316484493 hasConcept C118552586 @default.
• W2316484493 hasConcept C126322002 @default.
• W2316484493 hasConcept C142724271 @default.
• W2316484493 hasConcept C170493617 @default.
• W2316484493 hasConcept C177713679 @default.
• W2316484493 hasConcept C204787440 @default.
• W2316484493 hasConcept C27081682 @default.
• W2316484493 hasConcept C2777030092 @default.
• W2316484493 hasConcept C2777119127 @default.
• W2316484493 hasConcept C2778541695 @default.
• W2316484493 hasConcept C2778871607 @default.
• W2316484493 hasConcept C2778938600 @default.
• W2316484493 hasConcept C2779085531 @default.
• W2316484493 hasConcept C2780564907 @default.
• W2316484493 hasConcept C2780966972 @default.
• W2316484493 hasConcept C2908647359 @default.
• W2316484493 hasConcept C3017807917 @default.
• W2316484493 hasConcept C40993552 @default.
• W2316484493 hasConcept C42219234 @default.
• W2316484493 hasConcept C535046627 @default.
• W2316484493 hasConcept C71924100 @default.
• W2316484493 hasConcept C99454951 @default.
• W2316484493 hasConceptScore W2316484493C118552586 @default.
• W2316484493 hasConceptScore W2316484493C126322002 @default.
• W2316484493 hasConceptScore W2316484493C142724271 @default.
• W2316484493 hasConceptScore W2316484493C170493617 @default.
• W2316484493 hasConceptScore W2316484493C177713679 @default.
• W2316484493 hasConceptScore W2316484493C204787440 @default.
• W2316484493 hasConceptScore W2316484493C27081682 @default.
• W2316484493 hasConceptScore W2316484493C2777030092 @default.
• W2316484493 hasConceptScore W2316484493C2777119127 @default.
• W2316484493 hasConceptScore W2316484493C2778541695 @default.
• W2316484493 hasConceptScore W2316484493C2778871607 @default.
• W2316484493 hasConceptScore W2316484493C2778938600 @default.
• W2316484493 hasConceptScore W2316484493C2779085531 @default.
• W2316484493 hasConceptScore W2316484493C2780564907 @default.
• W2316484493 hasConceptScore W2316484493C2780966972 @default.
• W2316484493 hasConceptScore W2316484493C2908647359 @default.
• W2316484493 hasConceptScore W2316484493C3017807917 @default.
• W2316484493 hasConceptScore W2316484493C40993552 @default.
• W2316484493 hasConceptScore W2316484493C42219234 @default.
• W2316484493 hasConceptScore W2316484493C535046627 @default.
• W2316484493 hasConceptScore W2316484493C71924100 @default.
• W2316484493 hasConceptScore W2316484493C99454951 @default.
• W2316484493 hasIssue "3" @default.
• W2316484493 hasLocation W23164844931 @default.
• W2316484493 hasLocation W23164844932 @default.
• W2316484493 hasOpenAccess W2316484493 @default.
• W2316484493 hasPrimaryLocation W23164844931 @default.
• W2316484493 hasRelatedWork W159619527 @default.
• W2316484493 hasRelatedWork W2006390069 @default.
• W2316484493 hasRelatedWork W2020225664 @default.
• W2316484493 hasRelatedWork W2071609183 @default.
• W2316484493 hasRelatedWork W2111942126 @default.
• W2316484493 hasRelatedWork W2128656142 @default.
• W2316484493 hasRelatedWork W2136373160 @default.
• W2316484493 hasRelatedWork W2316484493 @default.
• W2316484493 hasRelatedWork W2336580589 @default.
• W2316484493 hasRelatedWork W77446864 @default.
• W2316484493 hasVolume "26" @default.
• W2316484493 isParatext "false" @default.
• W2316484493 isRetracted "false" @default.
• W2316484493 magId "2316484493" @default.

• next